Almudena Chaves Perez

Almudena Chaves Perez

Auto-generated profile, based on publicly available information

Almudena Chaves Perez

Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
RYRona Yaeger
Rona Yaeger
RMRiccardo Mezzadra
Riccardo Mezzadra
JSJenna Sinopoli
Jenna Sinopoli
YBYu Bian
Yu Bian
MMMichelangelo Marasco
Michelangelo Marasco
SMSandra Misale
Sandra Misale
With the combination of KRASG12C and EGFR inhibitors, KRAS is becoming a druggable target in colorectal cancer. However, secondary resistance limits its efficacy. Using cell lines, patient-derived xenografts, and patient samples, we detected a heterogeneous pattern of putative resistance alterations expected primarily to prevent inhibition of ERK signaling by drugs at progression. Serial analysis of patient blood samples on treatment demonstrates that most of these alterations are detected at a low frequency except for KRASG12C amplification, a recurrent resistance mechanism that rises in step with clinical progression. Upon drug withdrawal, resistant cells with KRASG12C amplification undergo oncogene-induced senescence, and progressing patients experience a rapid fall in levels of this alteration in circulating DNA. In this new state, drug resumption is ineffective as mTOR signaling is elevated. However, our work exposes a potential therapeutic vulnerability, whereby therapies that target the senescence response may overcome acquired resistance. Significance: Clinical resistance to KRASG12C–EGFR inhibition primarily prevents suppression of ERK signaling. Most resistance mechanisms are subclonal, whereas KRASG12C amplification rises over time to drive a higher portion of resistance. This recurrent resistance mechanism leads to oncogene-induced senescence upon drug withdrawal and creates a potential vulnerability to senolytic approaches. Watch the interview with Sandra Misale, PhD, recipient of the 2025 Cancer Discovery Early Career Award: https://vimeo.com/1100471486 This article is highlighted in the In This Issue feature, p. 1

31 May 2019 in Science
Verified
Journal Article
Closed access
PDF file
ACAlmudena Chaves-Pérez
Almudena Chaves-Pérez
MYMahmut Yilmaz
Mahmut Yilmaz
CPCristian Perna
Cristian Perna
SRSergio de la Rosa
Sergio de la Rosa
NDNabil Djouder
Nabil Djouder
Illuminating intestine irradiation: High-dose radiation exposure affects multiple body systems, including the blood and the neurovascular system. Radiation can also cause severe intestinal toxicity, known as gastrointestinal syndrome (GIS). Working in mice, Chaves-Pérez et al. focused on the mechanisms underlying GIS. The molecular chaperone URI (unconventional prefoldin RPB5 interactor) labeled slow-cycling label-retaining (LR) cells, which are essential for organ regeneration following ionizing radiation. Reduced URI levels rendered LR cells highly proliferative via the activation of the β-catenin/c-MYC axis. Consequently, LR cells became radiosensitive, increasing GIS severity. Thus, URI protects LR cells to promote tissue regeneration in response to high-dose irradiation. Science , this issue p. eaaq1165

29 April 2025 in Cancer Discovery
Verified
Journal Article
Open access
CBCaroline Broderick
Caroline Broderick
RMRiccardo Mezzadra
Riccardo Mezzadra
ESExequiel M. Sisso
Exequiel M. Sisso
FMFelix Mbuga
Felix Mbuga
RRRashi Raghulan
Rashi Raghulan
SLScott W. Lowe
Scott W. Lowe
Pharmacological inhibition of oncogenic RAS represents an attractive strategy to target pancreatic ductal adenocarcinoma (PDAC), an almost ubiquitously RAS-driven disease. However, initial responses to targeted monotherapy inhibition of active RAS can be followed by relapses, potentially driven by the persistence of drug-tolerant tumor cells. To target these “persister” cells, we investigated strategies to increase their immune visibility in mouse models of PDAC. We show that combining a RAS(ON) multi-selective inhibitor with the CDK4/6 inhibitor palbociclib drives persister cells into a senescent-like state, which coincides with improved tumor control and substantial remodeling of the tumor microenvironment. Combining RAS(ON) and CDK4/6 inhibition with a CD40 agonist results in durable regressions and CD4 T cell–dependent tumor-immune equilibrium. Our studies reveal a combinatorial approach that circumvents resistance to RAS(ON) inhibitor monotherapy in preclinical models and demonstrates a mechanism by which therapy-induced senescence can be reinforced by the immune system, resulting in durable tumor control. Significance: Our preclinical studies highlight an opportunity to exploit the senescence program and CD4 T cell–mediated mechanisms to achieve long-term tumor-immune equilibrium and control with RAS-targeted therapies. This work advances our understanding of therapy-induced senescence and suggests new avenues for combination therapies with the potential to benefit patients with PDAC. See related commentary by Lasse Opsahl and Pasca di Magliano, p. 1537

13 September 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ACAlmudena Chaves-Pérez
Almudena Chaves-Pérez
KSKarla Santos-De-Frutos
Karla Santos-De-Frutos
SRSergio de la Rosa
Sergio de la Rosa
IHIrene Herranz-Montoya
Irene Herranz-Montoya
CPCristian Perna
Cristian Perna
NDNabil Djouder
Nabil Djouder
Intestinal epithelium regenerates rapidly through proliferation of intestinal stem cells (ISCs), orchestrated by potent mitogens secreted within the crypt niche. However, mechanisms regulating these mitogenic factors remain largely unknown. Here, we demonstrate that transit-amplifying (TA) cells, marked by unconventional prefoldin RPB5 interactor (URI), control R-spondin production to guide ISC proliferation. Genetic intestinal URI ablation in mice injures TA cells, reducing their survival capacity, leading to an inflamed tissue and subsequently decreasing R-spondin levels, thereby causing ISC quiescence and disruption of intestinal structure. R-spondin supplementation or restoration of R-spondin levels via cell death inhibition by c-MYC elimination or the suppression of inflammation reinstates ISC proliferation in URI-depleted mice. However, selective c-MYC and p53 suppression are required to fully restore TA cell survival and differentiation capacity and preserve complete intestinal architecture. Our data reveal an unexpected role of TA cells, which represent a signaling platform instrumental for controlling inflammatory cues and R-spondin production, essential for maintaining ISC proliferation and tissue regeneration.

27 March 2025 in Blood
Verified
Journal Article
Open access
SMScott E. Millman
Scott E. Millman
ACAlmudena Chaves-Perez
Almudena Chaves-Perez
SJSudha Janaki-Raman
Sudha Janaki-Raman
YHYu-Jui Ho
Yu-Jui Ho
JMJohn P. Morris
John P. Morris
SLScott W. Lowe
Scott W. Lowe
Perturbations in intermediary metabolism contribute to the pathogenesis of acute myeloid leukemia (AML) and can produce therapeutically actionable dependencies. Here, we probed whether α-ketoglutarate (αKG) metabolism represents a specific vulnerability in AML. Using functional genomics, metabolomics, and mouse models, we identified the αKG dehydrogenase complex, which catalyzes the conversion of αKG to succinyl coenzyme A, as a molecular dependency across multiple models of adverse-risk AML. Inhibition of 2-oxoglutarate dehydrogenase (OGDH), the E1 subunit of the αKG dehydrogenase complex, impaired AML progression and drove differentiation. Mechanistically, hindrance of αKG flux through the tricarboxylic acid (TCA) cycle resulted in rapid exhaustion of aspartate pools and blockade of de novo nucleotide biosynthesis, whereas cellular bioenergetics was largely preserved. Additionally, increased αKG levels after OGDH inhibition affected the biosynthesis of other critical amino acids. Thus, this work has identified a previously undescribed, functional link between certain TCA cycle components and nucleotide biosynthesis enzymes across AML. This metabolic node may serve as a cancer-specific vulnerability, amenable to therapeutic targeting in AML and perhaps in other cancers with similar metabolic wiring.

4 August 2025
Verified
Other
Open access
PDF file
CBCaroline Broderick
Caroline Broderick
RMRiccardo Mezzadra
Riccardo Mezzadra
ESExequiel M. Sisso
Exequiel M. Sisso
FMFelix Mbuga
Felix Mbuga
RRRashi Raghulan
Rashi Raghulan
SLScott W. Lowe
Scott W. Lowe
Characterizing RAS(ON) inhibitor-based combination therapies in a differentiated mouse model of PDAC